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1. Introduction
Colorectal carcinoma (CRC) represents the most frequent malignancy of the gastrointestinal
tract in the Western world in both genders. There is a wide variation of incidence rate for
both colonic and rectal cancer among the populations of different countries: up to a 30-40-
fold difference is seen between North America (Canada, Los Angeles, San Francisco), New-
Zealand (non–Maori), Northern Italy (Trieste), Northern France (Haut- and Bas-Rhin) in
which the rate of CRC is around 50/100,000 inhabitants, and India (Madras, Bangalore, Tri‐
vadrum, Barshi, Paranda, Bhum, Karunagappally), Algeria (Setif), and Mali (Bamako) in
which the rate is around 3/100,000 [1]. It is estimated that approximately 6% of the United
States population will eventually develop a CRC, and that 6 million of American citizens
who are living will die of CRC [2].
The geographic differences in CRC incidence are due more to environment, life-style, and
diet than to racial or ethnic factors. Demonstration of this fact is that migrants from low to
high incidence areas have the same incidence as the host country within one generation,
having assimilate western lifestyle and diet [3].
Colonoscopy to screen asymptomatic adults older than 50 years allows an estimation of the
prevalence of adenomatous polyps or CRC: in North America CRC is found in 2%, and ad‐
vanced adenoma (more than 1 cm in diameter) in 10% [4[.
Population-based studies have investigated several environmental factors as contributors to
the initiation of sporadic colorectal carcinogenesis. High-calorie diet, high red meat con‐
sumption, overcooked red meat consumption, high saturated fat consumption, excess alco‐
hol consumption, cigarette smoking, sedentary lifestyle, and obesity are considered to
increase the incidence of CRC, while consumption of fiber, fresh fruit and vegetables, and a
high-calcium diet could have a protective effect [5]. A recent review [6] provided an over‐
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view of the epidemiological evidence supporting the roles of diet, lifestyle, and medication
in reducing the risk of colorectal cancer. Similarly, many studies that implicate effects of di‐
etary agents in various types of cancers are available and suggest that much of the suffering
and death from cancer could be prevented by consuming a healthy diet, reducing tobacco
use, performing regular physical activity, and maintaining an optimal body weight [7]. Even
if several epidemiological and experimental studies support the role of these factors in the
genesis of CRC, other well-designed prospective and randomized clinical trials conducted in
recent years report conflicting evidence, in particular on the role of the diet component in
the etiology of CRC [8, 9].
Meanwhile, the great majority of CRC are sporadic, with 2 to 6% of them related to a heredi‐
tary disease due to mutations of highly penetrant autosomic dominant genes. Mutations of
APC tumor suppressor gene is responsible for familial adenomatous polyposis (FAP), and
mutations of the mismatch repair (MMR) genes are related to hereditary non polypoid col‐
orectal cancer (HNPCC or Lynch’s syndrome). Mutations of MLH1 and MSH2 are responsi‐
ble for more than 90% of the family affected by HNPCC. In these familial events, the onset
of CRC is greatly anticipated in comparison to the sporadic counterpart which is usually di‐
agnosed after 50 years of age. However, an increasing incidence rate of CRC not clearly re‐
lated to the presence of inheritable or predisposing colonic diseases was observed in
individuals less than 40 years of age in recent decades [10]. Furthermore, an enhanced risk
for CRC and colonic adenomas is present in individuals whose first-degree relatives are af‐
fected by CRC, especially if the tumor occurs before the age of 60 [8]. Possible factors of this
inherited susceptibility to CRC are polymorphisms of genes deputed to glutathione synthe‐
sis such as GSTP1, GSTM1 and GSTT1 genes [11].
Prognosis of CRC is in relationship to local and distant tumor progression. Deep penetration
of carcinogenic cells in the colonic wall, invasion of adjacent organs, diffusion in lymph no‐
des or peritoneum, and distant metastases must be evaluated for staging of the disease and
correct therapeutic planning. One third of all colorectal tumors are located in the rectum:
prognosis of distally sited rectal cancer is worse than that of proximally sited rectal cancer or
of colonic cancer. Despite great advances in population screening, early diagnosis, surgical
interventions, and complementary therapies, long-term survival for CRC remains in the
range of 50-60%.
Tumor formation in humans is a multistage process involving a series of events, and gener‐
ally occurs over an extended period. During this process, several genetic and epigenetic al‐
terations lead to the progressive transformation of a normal cell into a cancer cell. These
cells acquire various abilities that transform them into malignant cells: they become resistant
to growth inhibition, proliferate without dependence on growth factors, replicate without
limit, evade apoptosis, and invade, metastasize, and support angiogenesis. Mechanisms by
which cancer cells acquire these capabilities can vary considerably, but most of the physio‐
logical changes associated with these mechanisms involve alteration of signal transduction
pathways [7].
It  is  commonly  agreed  that  the  first  step  of  colorectal  tumorigenesis  is  the  shift  of  the
proliferative zone in the glandular crypts,  accompanied by the development of  aberrant
Soybean - Bio-Active Compounds76
crypt foci,  and followed by the formation of  an adenomatous polyp.  These pathological
features are considered the precursor of the carcinoma in a temporal sequence that also
can be completed in several years.  However,  CRC is not a homogenous disease:  several
histological  types  can  be  distinguished  such  as  tubular  or  villous,  mucinous,  serrated,
medullary,  signet-ring,  squamous  cell,  adenosquamous,  small  cell,  and undifferentiated,
and different molecular basis  can also be recognized in histologically similar tumors.  In
recent  years,  the identification of  the genetic  mutations of  hereditary forms of  CRC has
clarified two fundamentals  types of  carcinogenesis.  The first  is  similar  to that  described
for  the development of  the FAP,  and is  characterized by a  progressive accumulation of
genetic changes starting from a biallelic inactivation of APC.  Additional mutations either
of oncogenes KRAS  and p53  or of oncosuppressor genes (DCC  and DPC4)  are necessary
for the neoplastic progression and invasivity [12]. The genetic alterations are responsible
for an increased mucosal proliferation and a reduced apoptosis, causing a clonal cellular
expansion. The second, similar to the CRC arising in the HNPCC, is due to inactivation
of  MLH1  or  of  other  MMR  genes.  Repetitive  sequences  of  DNA,  sited in  non-encoding
microsatellite regions throughout the genome, are specifically found in this type of CRC,
hence,  the  definition  of  micro  satellite  instability  (MSI).  The  mechanism responsible  for
the  carcinogenesis  is  epigenetic  due  to  an  extensive  DNA  methylation.  Rarely  in  this
type  of  CRC  both  proto-oncogenes  (KRAS,  p53)  and  oncosuppressor  genes  (APC,
TGFBRII,  IGF2R,  BAX)  are  mutated  or  inactivated  [13].  The  former  genetic  mechanism
explains the most  frequent  form of  sporadic CRC characterized by the sequence adeno‐
ma-carcinoma and a long period for the formation of cancer; vice versa, the last mecha‐
nism  is  only  present  in  15%  of  sporadic  CRC,  and  can  have  the  character  of  an
accelerated carcinogenesis.
Improved knowledge of the molecular mechanisms of colorectal  carcinogenesis allows a
rationale chemopreventive use in individuals  who have an increased risk of  developing
colorectal  adenomas or  cancer.  Both natural  or  synthetic  agents  have been employed to
prevent or  suppress the colorectal  tumorigenesis.  In particular,  in experimental  animals,
cohort  and clinical  case-control  studies have shown inverse association between the use
of  either  anti-inflammatory  non  steroidal  drugs  (NSAIDs),  estrogens  or  phytoestrogens,
and incidence of both colonic adenomas and CRC. NSAID use appears to prevent the oc‐
currence  of  carcinogen-induced animal  colonic  tumors  [14]  and to  decrease  the  number
and  size  of  colo-rectal  polyps  in  FAP  (Familial  Adenomatous  Polyposis)  patients  [15].
Randomized placebo controller  trials  showed that  aspirin  reduced the  risk  of  colorectal
adenomas  in  populations  with  an  intermediate  risk  of  developing  adenomas  [16].  Fur‐
thermore, NSAIDs or selective COX-2 inhibitors reduce the in vitro growth of human co‐
lon  cancer  cell  [17].  The  effect  of  NSAIDs  is  mediated  by  cell  cycle  arrest  due  to
inhibition  of  the  Wnt-signaling  pathway that  favors  the  phosphorilation  of  beta-catenin
and by induction of apoptosis [18, 19].
The fact that estrogens have an effect in decreasing the risk of colo-rectal cancer is shown by
the following data:
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1. Several epidemiologic studies show a smaller incidence of sporadic CRC in the female
gender. Also the occurrence of CRC in HNPCC is lower in females than in males;
2. women who are multipare are a reduced risk of CRC in confront to nullipare;
3. epidemiologic studies of postmenopausal women show that users of HRT have a signif‐
icant reduction of CRC development in respect to women who had never used HRT.
The risk appears to be halved with 5-10 years of HRT use [20, 21];
4. use of non-contraceptive hormones for more than 5 years reduces by (OR = 0.47, 95 per‐
cent CI = 0.24-0.91) the risk of colon cancer [22].
2. Nutrition and colon cancer
It is now believed that 90–95% of all cancers are attributed to lifestyle, with the remaining 5–
10% attributed to faulty genes [7]. Almost 30 years ago epidemiological research suggested
that appropriate nutrition could prevent approximately 35% of cancer deaths, and up to 90%
of certain cancers could be avoided by dietary enhancement [23, 24].
Colon cancer is a multifactorial disease that results from the interaction of different factors
such as aging, family history, and dietary style. Identifying modifiable factors associated
with colorectal cancer is of importance, the ultimate goal being primary prevention, and
particularly the role of diet in the aetiology, initiation, and progression of colorectal cancer
remains an area of important research. Moreover, several components of food can exert a
potent activity also in the later stages of cancer. Several studies have indicated that inhibi‐
tion of metastasis by genistein, one of the most important constituents of soy foods, repre‐
sents an important mechanism by which it is possible to reduce mortality associated with
solid organ cancer.
Many plant-derived dietary agents have multitargeting properties and are therefore called
nutraceuticals. A nutraceutical (a term formed by combining the words “nutrition” and
“pharmaceutical”) is simply any substance considered to be a food or part of a food that
provides medical and health benefits. During the past decade, a number of nutraceuticals
have been identified from natural sources. Nutraceuticals are chemically diverse and target
various steps in tumor cell development [7].
Several epidemiological studies have consistently shown an inverse association between
consumption of vegetables and fruits and the risk of human cancers at many sites. Wickia &
Hagmannc (2011) recently reported that many case-control and cohort studies are dealing
with the effect of fruits and vegetables on cancer incidence [25]. Early data indicated a bene‐
ficial effect [26] and, as recently as 2008, Freedman et al. found a reduced occurrence of head
and neck cancers with increased fruit and vegetable consumption [27].
The concept that a diet that is high in fiber, especially from fruits and vegetables, lowers risk
of colorectal cancer has been in existence for more than 4 decades. The majority of case-con‐
trol studies have shown an association between higher intake of fiber, vegetables, and possi‐
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bly fruits, and lower risk of colon cancer [28]. A meta-analysis of six case-control studies
found that a high intake of vegetables or fiber was associated with an approximate 40%–50%
reduction in risk for colon cancer [29]. Similarly, a pooled analysis of 13 case-control studies
reported an approximately 50% lower risk of colon cancer associated with higher intake of
fiber [30].
Increasing intake of fruits, vegetables, or fiber is unlikely to prevent a large proportion of
colorectal cancers, particularly among the US population, which has a food supply already
fortified with folate and other dietary factors that might protect against colorectal neoplasia.
There is also little evidence that concentrated sources of one type of fiber are efficacious, al‐
though fiber-rich diets have health benefits for other gastrointestinal conditions, such as di‐
verticular disease and constipation, and possibly other chronic diseases [6].
All  evidence  supporting  the  decreased  risk  include  results  from  a  few  studies  of  ade‐
nomatous polyps (which may progress  to  colorectal  carcinomas).  Fruit  and grain intake
also appears to be inversely related to risk of colorectal cancer and polyps, although less
consistently  than  vegetables.  These  potentially  protective  associations  may  result  from
the high levels of dietary fibres, antioxidants (e.g., beta-carotene, vitamin C), or other an‐
ticarcinogenic  constituents  (e.g.,  protease  inhibitors,  phytoestrogens)  in  these  vegetables,
fruits,  and  grains.  However,  the  association  of  adenomatous  polyps  of  the  large  bowel
with  intake  of  vegetables,  fruits,  and  grains  has  not  been  studied  to  any  great  degree,
and existing data on these associations are not entirely consistent.  Because adenomatous
polyps are precursors to colorectal cancer, studying polyps instead of cancer might allow
one to measure the diet of relatively asymptomatic subjects closer to the time of the ini‐
tial neoplastic process. [31].
A recent meta analysis and data review, conducted by Magalhães B. [32], substantiates that
the risk of colon cancer was increased with patterns characterized by high intake of red and
processed meat, and decreased with those labelled as 'healthy.'
There are many plausible mechanisms by which intake of vegetables, fruits and “healthy
foods” may prevent carcinogenesis.
Plant foods contain a wide variety of anticancer phytochemicals with many potential bioac‐
tivities that may reduce cancer susceptibility [7,33, 34].
3. Soyfoods and colon cancer
Many epidemiologic studies evidence a lower rate of hormone-related cancers among Asian
populations which are characterized by regular consumption of soy based foods. Soy is a
major plant source of dietary protein for humans. A review of epidemiologic studies (most
of which were case-control studies published before 2000) suggested an inverse association
between high soy intake and colon cancer risk in humans [35]. Moreover, migration studies
show that Japanese immigrants in the United Status have incidence rates of colorectal can‐
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cers very near to the rates among the whites in the country [6]. Thus the protective effect of
soy foods and isoflavones is a matter of interest in the etiology of colorectal cancer.
Soy and soy foods contain a wide variety of chemical compounds, biologically active, that
may contribute, individually or synergistically, to the health benefits of this plant; in partic‐
ular, polyphenols are considered to possess chemopreventive and therapeutic properties
against cancer.
Among these compounds, certainly, there are isoflavones, the most important and abundant
of which is genistein, which also have estrogenic properties. In fact, in recent decades, there
have been several studies showing that isoflavones are promising candidates for cancer pre‐
vention [36, 37, 38, 39].
Data associating soybean consumption with reduced cancer rates have been used as evi‐
dence for a role of isoflavones in cancer prevention. However, soybeans are also a rich
source of trypsin inhibitor, other proteins with health benefits, phosphatidyl inositol, sapo‐
nins, and sphingolipids, all of which have potential health benefits. All of these soybean
constituents demonstrate tumor preventive properties in animal models. Research by Birt et
al. demonstrated that 20% by weight of dietary soy protein significantly reduced rat intesti‐
nal mucosa levels of polyamine, a biomarker of cellular proliferation for colorectal cancer
risk [39].
Surely, soy foods are complex foods, and it is difficult to assume that associations which
suggest protective properties of soy foods are due only to a single constituent. Because of
the association between diets in Japan and China and lower rates of cancers, such as those of
the breast, prostate, and colon, than in Europe and the United States, many investigators
have assumed that this is due to soy food consumption in Japan and China.
Other factors in the Asian diet may be responsible, and it’s important to evaluate the possi‐
ble confounding dietetic factors in the studies.
Several studies suggest that soy foods, the predominant source of isoflavones, are associated
with reductions in cancer rate, but they do not consistently appear to be the primary protec‐
tive component of the Asian diet.
Wu et al. noted the difficulties in assessing the relationship between the level of intake and
protection. Case control and prospective epidemiological investigations that have provided
a suggestion of protection against cancer by soy foods have not provided adequate informa‐
tion on the bioactive constituents in the soy foods, the portion size, or other components that
may be protective in the diets of people who eat soy foods [40].
Isoflavones and flavonoids may be rapidly and predominately glucuronidated in the GI mu‐
cosa, if genistein can be considered a model for all of these phenolic compounds [41]. Fur‐
ther, glucuronidation occurs in the liver. Genistein undergoes biliary excretion, with more
than 70% of a dose recovered in bile within 4 hr after dosing in rats. Although genistein may
be absorbed well initially, a maximum of 25% of an oral genistein dose would be eliminated
in rat urine. About 20–25% of an oral dose of genistein (predominantly as its glucoside from
soy foods) is recovered in human urine [42, 43].
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The presence of hydroxylated and methylated genistein metabolites correlated positively
with inhibition of cancer cell proliferation, but genistein sulfates were not associated with
antiproliferative effects of genistein, suggesting that some types of metabolism of the isofla‐
vones may be crucial for their action [44].
Witte, et al, showed that higher consumption of tofu (or soybeans) was inversely associated
with polyps. Tofu (or soybeans) contain a number of potentially anticarcinogenic constitu‐
ents, including isoflavones, saponins, genistein, and phytosterols. They were able to look at
tofu (or soybeans) as a single food item (i.e., separate from legumes) because almost 15 per‐
cent of our multiethnic study population reported consuming tofu (or soybeans) at least
once a week. The strongest association observed was for vegetables—including those high
in carotenoids, cruciferae, and broccoli—as well as garlic and tofu (or soybeans), and these
associations were found even after adjusting for dietary fiber, folate, beta-carotene, vitamin
C, and other commonly measured antioxidants [31].
Men tend to have a slightly higher incidence of colorectal cancer than women of similar age
(American Cancer Society, 2007), and oestrogen seems to be implicated for this decreased
risk in women. Epidemiological studies and results of a Women’s Health Initiative (WHI)
clinical trial provide strong evidence that colorectal cancer is hormone sensitive because the
cancer risk is reduced by post-menopause hormone therapy [35]
In effect, many epidemiological and experimental studies suggest a protective role of estro‐
gens against colorectal cancer. The decrease in the number of deaths from large bowel carci‐
noma observed in the United States in the last 40 years was significantly higher in women
(30%) as compared to men (7%). A link was observed between oral contraceptive use and a
reduction of colorectal cancer, whereas there was a higher than expected frequency of color‐
ectal tumors among non users [45].
Interestingly, as reported by Barone et al., although several experimental studies have con‐
firmed a protective role of estrogens for CRC, few studies have been conducted, and with
conflicting results, on the possible protective effect of estrogens against the development of
adenomatous polyps in the colon, although it is well known that the development of adeno‐
carcinoma mostly involves polyp formation [46].
Gender differences in the incidence and behavior of colorectal cancer (CRC), as well as epi‐
demiologic data indicating a protective effect of hormone replacement therapy in women,
have further supported the concept of hormonal influence on the development of CRC. It
has been suggested that the protective effect of estrogens (or phytoestrogens) may be medi‐
ated through activation of ERβ, which has been shown to be the predominant subtype of ER
in the gastrointestinal tract [47].
ERs are nuclear receptors belonging to the steroid hormone receptor superfamily which
have the characteristic of being activated upon binding of the ligand. If the ligand is not
present,  ERs  bind  to  a  shock  protein.  Otherwise,  when  the  ligand  is  present,  the  ERs
make  a  stable  dimer  and  initiate  the  specific  estrogenic  response,  with  transcription  of
the target genes. Two main types of ER have been identified: alfa (ERα) and beta (ERβ).
They  are  the  so-called  ligand-activated  transcriptional  factors  through  which  estrogens
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exert  their  effects  on  various  tissues  and  have  a  different  tissue  distribution.  ERα  is
mainly present in the mammary glands and in the utterus; ERβ is mainly present in en‐
dothelial  cells,  the urogenital  tract,  the central  nervous system, and the colonic mucosa.
Experimental data have demonstrated that CRC express an elevated number of estrogen
receptors (ERs), but while ERα is detected in very low levels either in normal or patho‐
logical  colonic mucosa (adenoma and carcinoma),  ERβ expression is  high in the normal
colonic  mucosa,  and progressively  decreased in  the  pathological  mucosa  in  relationship
to the cellular differentiation and CRC stage.
The observation that the level of ERβ protein is lower in malignant tumors than in normal
tissue of the same organ has fostered the hypothesis that ERβ may function as a tumor sup‐
pressor, protecting cells against malignant transformation and uncontrolled proliferation.
ERβ is present in various isoforms: studying different types of colonic tumoral cells, isoform
1 of ERβ is found in the Lo-Vo, HCT8, HCT116, DLD-1 and isoform 2,3,4 and 5 only in the
HCT8 and HCT116. It has not been well investigated whether the function of the various
isoforms of ERβ, but loss of the expression of isoform 1 of ERβ, is accompanied by undiffer‐
entiated proliferation, mucinous histological type, and tumor progression [48]. It is accepted
that the binding of estrogens to the ERβ blocks the activity of AP-1 on the genes involved in
the cellular proliferation and provokes an activation of p53. Conversely, SERM, such as ta‐
moxifene and raloxifene, induce an antiproliferative effect in human colorectal cell lines by a
citostatic or cytotoxic effect [49]. Several observations on the CRC cellular cultures and on
the experimental mouse with germinal mutation of APC have clarified the role of the ER
and estrogenes for colorectal cancerogenesis: 17β estadiol decreases the proliferation in vitro
of the HCT116, Lo-Vo and DLD1 cells, but increases the proliferation of the HCT8 cells.
However, the effect on the last type of cells is completely changed by increasing the level of
RRb by transfection with ERβ. The overexpression of ERβ can have an inhibitory effect on
the proliferation. In the transfected HCT8 cells the levels of CD4 and CP21, which are onco‐
suppressor genes, are significantly increased, and the level of cyclinE, which have oncogenic
activity, significantly decreased, in respect to normal HCT8 [50].
ERβ is lower in the adenomatous polyps of FAP patients and in the intestinal adenomas
which develop in APC Min+/- mouse than in the colonic normal mucosa. The restoration of
normal levels of ERβ obtained with dietary phytoestrogenes is accompained by regression
or disappearance of the polyps in the experimental animal. Patients with sporadic adenomas
in the colon show an increase of apoptoic activity, and ERβ expression of the colonic muco‐
sa, if their diet is supplemented by phytoestrogenes [45]. These data strongly support a piv‐
otal role of ERβ in a protective action against the initiation and progression of colorectal
carcinogenesis.
Many epidemiologic studies evidence a lower rate of hormone-related cancers among Asian
populations which are characterized by regular consumption of soy based foods. Soy is a
major plant source of dietary protein for humans. Among other components, soy contains
large amounts of phytoestrogens.
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As proposed for estrogens, genomic and non-genomic mechanisms have also been suggest‐
ed for phytoestrogens to explain their biological activities
As reported by several authors in the past, genomic pathways are mediated through the
ability of phytoestrogens to interact with enzymes and receptors, and cross the plasma
membrane. In this way, they bind ERs and induce the transcription of estrogen-responsive
genes, stimulate cell growth in the breast, and modify ER transcription itself. However,
some of their effects are not due to interaction with ERs, and are therefore denominated
non-genomic effects. For example: inhibition of tyrosine kinase and DNA topoisomerase,
suppression of angiogenesis, and antioxidant effects [33, 36, 46].
The  bioavailability  of  phytoestrogens  (determined  by:  absorption,  distribution,  metabo‐
lism  (bioconversion  in  the  gut  and  biotransformation  in  the  liver)  and  escretion)  and
their  activity is  highly variable and changes with respect  to several  factors,  such as ad‐
ministration  rules,  dosage,  metabolism and interaction  with  other  pharmacological  sub‐
stances.  Moreover,  their  biological  effect  is  influenced  by  the  type  of  target  tissue,  the
number and type of ERs expressed in the tissue, their serum concentration, and sex ste‐
roid hormone concentration [51, 52].
Phytoestrogens, present in soy and soy-based food, may act through hormonal mechanisms
to reduce cancer risk by binding to estrogen receptors (ER) or interacting with enzymes in‐
volved in sex steroid biosynthesis and metabolism [53].
Although cancer incidence in women is much lower than in men in both countries, there is
also a difference when the 2 countries are compared. Japanese men as well as women have a
lower colorectal cancer incidence than their American counterparts, although mortality is
quite similar when related to specific incidence data. In hormone-dependent cancers such as
those of the breast and prostate, incidence is exceedingly low in Japan (and was even lower
in earlier decades) compared with that in the United States. Mortality, again in proportion to
incidence, is rather similar. Numerous reports have suggested that this difference in tumor
incidence is probably due to consumption of soy as a staple food in Asian countries in con‐
trast to Western industrialized countries. These substances, through their potential to act as
selective estrogen receptor modulators, may affect vitamin D–related inhibition of tumor
growth by upregulating extrarenal synthesis of 1,25- D3. Genistein, the most prominent
phytoestrogen in soy, is known to regulate other P450 enzymes, such as 5-reductase and 17-
hydroxysteroid dehydrogenase, which are essential for metabolism of sex hormones [54].
In vitro studies of DLD1 colon adenocarcinoma cells have linked the effects of soy with es‐
trogen receptor beta. Experiments conducted on this cell line, with or without ER-β gene si‐
lencing by RNA interference (RNAi), have shown that soy isoflavones decreased the
expression of proliferating cell nuclear antigen (PCNA), extracellular signal-regulated kin‐
ase (ERK)-1/2, AKT, and nuclear factor (NF)-κB. Soy isoflavones dose-dependently caused
G2/M cell cycle arrest and downregulated the expression of cyclin A. This was associated
with inhibition of cyclin dependent kinase (CDK)-4 and upregulation of its inhibitor p21 ex‐
pressions. ER-β gene silencing lowered soy isoflavone-mediated suppression of cell viability
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and proliferation. ERK-1/2 and AKT expressions were unaltered and NF-κB was modestly
upregulated by soy isoflavones after transient knockdown of ER-β expression.
Soy isoflavone-mediated arrest of cells at G2/M phase and upregulation of p21 expression
were not observed when ER-β gene was silenced. These findings suggest that maintaining
the expression of ER-β is crucial in mediating the growth-suppressive effects of soy isofla‐
vones against colon tumors. Thus, upregulation of ER-β status by specific foodborne ER-li‐
gands such as soy isoflavones could potentially be a dietary prevention or therapeutic
strategy for colon cancer [55].
4. Genistein and isoflavones: Other mechanisms of action
In addition to estrogenic/antiestrogenic activity, some mechanisms of action have been iden‐
tified for isoflavone/flavone prevention of cancer: antiproliferation, induction of cell cycle
arrest and apoptosis, prevention of oxidation, induction of detoxification enzymes, regula‐
tion of host immune system, and changes in cellular signaling [39, 56, 57]. It is expected that
also combinations of these mechanisms may contribute to cancer prevention.
Gene silencing due to the promoter methylation provides an opportunity for clinical inter‐
vention, as gene-re-expression can be induced by a variety of DNA demethylating agents.
Recent studies show that genistein may affect DNA methylation, serves as a natural deme‐
thylation agent, and that it is specifically effective on colon cancer cells from early-stage co‐
lon cancer [58]. WNT family members are highly conserved, secreted signaling molecules
that play important roles in both tumorigenesis and normal development and differentia‐
tion. Study of Hibi et al. evidences that genistein treatment affected the DNA methylation of
WNT5a, and that WNT5a downregulation is correlated with hypermethylation of its promot‐
er in human colon cancer patients [60, 59].
Moreover, genistein may inhibit cancer progression by inducing apoptosis or inhibiting pro‐
liferation, and the mechanisms by which genistein exerts its anti-tumor effects has been the
subject of considerable interest [61, 62, 63].
Genistein has been shown to induce epigenetic changes in several cancer cell lines and in the
in vivo animal models. [64].
The presence of hydroxylated and methylated genistein metabolites correlated positively
with inhibition of cancer cell proliferation, but genistein sulfates were not associated with
antiproliferative effects of genistein, suggesting that some types of metabolism of the isofla‐
vones may be crucial for their action.
Genistein is a known inhibitor of protein-tyrosine kinase (PTK), which may attenuate the
growth of cancer cells by inhibiting PTK-mediated signaling mechanisms [65]. Sakla et al.
(2007) recently reported that genistein inhibits the protooncogene HER-2 protein tyrosine
phosphorylation in breast cancer cells as well as delaying tumor onset in transgenic mice
that overexpress the HER-2 gene. These data support its potential anti-cancer role in chemo‐
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therapy of breast cancer. However, effects independent of this activity have also been dem‐
onstrated [66, 67].
Soy isoflavone supplemented diets also prevented the development of adenocarcinomas in
the prostate and seminal vesicles in a rat carcinogenesis model [68].
Phytoestrogens,  present  in  soy  based  food,  may  act  through  hormonal  mechanisms  to
reduce cancer risk by binding to estrogen receptors (ER) or interacting with enzymes in‐
volved in sex steroid biosynthesis and metabolism [53].  Moreover,  genistein may inhibit
cancer  progression  by  inducing  apoptosis  or  inhibiting  proliferation,  and  the  mecha‐
nisms by which genistein exerts its anti-tumor effects have been the subject of consider‐
able interest [61, 62, 63].
Studies demonstrate that ERβ is highly expressed in superficial and crypt epithelium of the
normal colon in both genders. ERβ expression was highly correlated among all cell types in
both genders, and the strongest correlation was observed between surface and crypt ERβ ex‐
pression. This finding suggests that there may be an intersubject difference in ERβ expres‐
sion that is manifested in all cell types. ERβ expression was significantly lower in colon
cancer cells compared with normal colonic epithelium, and there was a progressive decline
in ERβ expression that paralleled the loss of cancer cell differentiation. The present findings
are consonant with previous results reported by Foley and colleagues [69], who also detect‐
ed a loss of ERβ protein expression in malignant colon tissue by western immunoblotting.
Another immunohistochemical study of ERβ in 55 patients with colorectal adenocarcinomas
showed that 32% of all tumors in both genders were ERβ-negative; the 10% cut-off threshold
was used to distinguish ERβ-positive from negative tumors [70].
Studies conducted with ER subtype-specific ligands and those performed with estrogen re‐
ceptor b-knockout mice (ERβKOs) have illustrated the involvement of ERβ in cellular anti-
inflammatory pathways and tissue homeostasis in the colon. These results suggest that ERβ-
specific ligands may be promising targets in the pharmaceutical and therapeutical treatment
of inflammatory bowel disease and the prevention of CRC. ERβKOs suggest that ERβ-spe‐
cific agonists and ERβ-selective phytoestrogens like genistein (GEN) and coumestrol may
serve as potential regulators of intestinal tissue homeostasis [71, 72, 73].
Schleipen et al. investigate the influence of ERα and ERβ-specific agonists, and of genestein
on cell proliferation and apoptosis of the small intestine and the colon. Recent data indicate
that ERβ-specific agonists and GEN inhibit epithelial proliferation of the prostate and mam‐
mary gland, and can even impede prostate cancer development [74, 76, 75]. It can therefore
be assumed that ERβ-specific agonists may also inhibit the proliferation of the intestinal epi‐
thelium. To prove this hypothesis in the study, ovariectomized rats were treated with 17β-
Estradiol (E2), the phytoestrogen GEN and ER subtype-specific agonists for ERα and ERβ
for 3 weeks.
Genistein has been shown to induce epigenetic changes in several cancer cell lines and in in
vivo animal models [64]. Recent studies show that genistein may affect DNA methylation,
serves as a natural demethylation agent, and is specifically effective on colon cancer cells
from early-stage colon cancer [58].
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WNT family members are highly conserved, secreted signaling molecules that play impor‐
tant roles in both tumorigenesis and normal development and differentiation. Study of Hibi
et al. evidence that genistein treatment affected the DNA methylation of WNT5a, and that
WNT5a down-regulation is correlated with hypermethylation of its promoter in human co‐
lon cancer patients [59, 60]. Aberrant WNT signaling is considered one of the most correlat‐
ed factors in over 90% of both benign and malignant colorectal tumors [77].
Many epigenetic silencing and activating events have been discovered in the WNT pathway
that are also related to aberrant WNT signaling, including aberrant expression of sFRP1,
DKK1, and APC [78, 79]. Therefore, Wang and Chen investigate the effect of genistein on
WNT pathway regulation in colon cancer development [58]. This study showed that: genis‐
tein treatment selectively induced WNT5a expression in specific colon cancer cell lines;
WNT5a showed the lowest expression compared to other more advanced tumor cell lines;
and the novel finding that WNT5a mRNA expression was upregulated by genistein in this
early-stage colon cancer cell line.
These results support the notion that genistein serves as a natural demethylation agent and
that it is specifically effective on colon cancer cells from early-stage colon cancer. Genistein
treatment affected the DNA methylation of WNT5a. It has been shown that WNT5a downre‐
gulation is correlated with hypermethylation of its promoter in human colon cancer patients
[59, 60].
Wang and Chen studies showed that the time dependent induction of WNT5a by genistein
in colon cancer cell line SW 1116 was correlated with decreased methylation of a CpG island
within its promoter, as determined by bisulfate sequencing [58].
Demethylation of CpGs inhibition of Dnmt and MBD2 activity, and activation of the histo‐
nes by acetylation and demethylation at the BTG3 promoter followed by genistein treat‐
ment, were observed in renal cancer cells [80]. Using the mouse differential methylation
hybridization array, alteration of DNA methylation in specific genes in mice was observed
following feeding of a diet containing genistein compared to that in mice fed a control ca‐
sein diet [81].
Other direct evidence that genistein affected DNA methylation was that maternal exposure
to dietary genistein altered the epigenome of offspring in viable yellow agouti (Avy/a) mice.
Overall, the potential of genistein as an effective epigenome modifier, which may greatly
impact CRC metastasis, highlights the potential ability of dietary genistein to improve CRC
prognosis [82].
Downregulation by promoter hypermethylation occurs in cell lines from earlier stages of co‐
lon cancer but not in cell lines from later stages.
These findings suggest that maintaining the expression of ER-β is crucial in mediating the
growth-suppressive effects of soy isoflavones against colon tumors. Upregulation of ER-β
by specific foodborne ER-ligands, such as soy isoflavones, could potentially be a dietary pre‐
vention strategy for colon cancer. [55].
Soybean - Bio-Active Compounds86
Genistein  has  been  shown  to  inhibit  cancer  metastasis  through  its  ability  to  regulate
nearly every step of  the metastatic  cascade,  including cell  adhesion,  migration invasion,
and angiogenesis.  The effect  of  genistein on the metastaic  cascade involves many meta‐
stasis suppressor or related signaling pathways, such as NFKappaB. Genistein can affect
both  of  these  processes,  as  well  as  modulate  key  regulatory  protein  such  as  Akt  and
nuclear  factor  κB  (NF-κB).  In  general,  low-to-mid  micro  molar  concentrations  of  genis‐
tein  are  required  for  these  effects  in  cell-culture-based  models,  although,  interestingly,
effects  in  animal  models  have been observed at  lower concentrations.  Genistein inhibits
critical pathways in cancer invasion and can specifically target MEK4. This inhibition re‐
sults  in  inactivation  of  the  MEK4  pathway,  decreased  MMP-2  production,  and  de‐
creased cell invasion. Genistein also activates Smad1, which is activated by the endoglin
signaling  pathway,  and  causes  decreased  cell  invasion.  Additionally,  genistein  inhibits
FAK activation,  resulting  in  increased cell  adhesion.  At  this  time,  it  is  unclear  whether
the  activation  of  Smad1  and  FAK  are  due  to  genistein’s  inhibition  of  MEK4  or  via  a
different signaling mechanism [83].
Several reports have demonstrated that genistein can induce cell cycle arrest and that it can
therapeutically modulate key regulator cell cycle proteins at concentrations ranging from 5
to 200 μM [84]. It is important to note that these concentrations are greater than the blood
levels that are observed with dietary consumption, indicating that this is likely not the pri‐
mary mechanism by which genistein inhibits metastasis. However, it is theoretically possi‐
ble to achieve these levels in humans, and various animal studies have also demonstrated
that genistein can reduce the primary tumor size in certain contexts.
Studies by Wentao et al.  show that genistein inhibits EGF induced loss of FOXO3 activ‐
ity  by  targeting  the  PI3K/  Akt  pathway.  Downstream,  genistein  inhibits  EGF  induced
FOXO3 disassociation from p53(mut),  which further promotes FOXO3 activity and leads
to  increased  expression  of  the  p27kip1  cell  cycle  inhibitor,  which  inhibits  proliferation
in colon cancer  cells.  The author demonstrated that  one of  the anti-proliferative mecha‐
nisms of genistein in colon cancer cells is to promote FOXO3 activity by inhibiting EGF-
induced  FOXO3  phosphorylation  (inactivation)  via  the  PI3K/Akt  pathway.  Active
FOXO3 negatively regulates proliferation of colon cancer cells  and shows that its  inacti‐
vation is an essential step in EGF-mediated proliferation [85, 86].
5. Conclusion
Several studies shown that consumption of fiber, fresh fruit and vegetables, a high-calcium
diet could have a protective effect on the increased risk of colorectal cancer, and suggest that
much of the suffering and death from cancer could be prevented by consuming a healthy
diet, reducing tobacco use, performing regular physical activity, and maintaining an optimal
body weight [5].
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Soy is one of the most consumed foods worldwide. Soy foods contain larger amounts of
phytoestrogens of which the isoflavon genistein is surely the biologically most important.
This compound, in recent years, has received much attention in the field of oncology re‐
search, as it exerts a wide range of biological effects of direct relevance to cancer.
Phytoestrogens and in particular genistein, have shown to be an important tool for the in‐
hibition of cancer metastasis, exerting effects on both the initial steps of primary tumor
growth as well as the later steps of the metastatic cascade.
The international literature suggests that phytoestrogens have potentially a high clinical im‐
pact and the expansion of knowledge on soy, soy foods, and soy products will lead to novel
future developments in the field of cancer treatment.
Phytoestrogens in soy foods





Soy cheese american 17.95
Soy flour (textured) 172.55
Soy milk 10-200
Soy milk curd, dried 83.30
Soy milk fortified or unfortified 10.73
Soy milk skin or film (Foo jook or yuba), cooked 44.67
Soy milk skin or film (Foo jook or yuba), raw 196.05
Soy protein concentrate 94.65
Soy protein drink 81.65
Soy protein isolate 91.05
Soy yogurth 33.17
Tempeh 60.61
Tofu (dried frozen) 83.20
Tofu raw regular with calcium and sulphate 22.73
Tofu yogurt 16.30
Table 1. Isoflavone Content of Selected Soy Foods (USDA Database 2008)
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Figure 1. Chemical structures of soy phytoestrogens are similar to17 beta estadiol
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